This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Add Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.
3 Reasons Growth Investors Will Love McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.
3 Reasons to Add McKesson (MCK) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.
Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Faster adoption of digital health and recent partnerships are expected to have contributed to Walgreens' (WBA) first-quarter performance.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.
Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System
by Zacks Equity Research
Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.
Abbott (ABT) Diagnostic and Nutrition Arms Grow Worldwide
by Zacks Equity Research
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline
by Zacks Equity Research
IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.
McKesson (MCK) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption
by Zacks Equity Research
Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.
LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.
BD (BDX) Partners With Retailers for At-Home COVID-19 Test
by Zacks Equity Research
BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.
Thermo Fisher (TMO) Releases New Update for Omicron Detection
by Zacks Equity Research
Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.
Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM
by Zacks Equity Research
CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.
Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.